ReviewHarvard review of psychiatry
Pharmacotherapy for alcohol use disorder: current and emerging therapies.
Review in Harvard review of psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05458609 (Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep: A Randomized, Double-Blind, Placebo- Controlled Study
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Long-term Efficacy and Safety of Sodium Oxybate in Treating Alcohol Use Disorder: A Systematic Review and Meta-Analysis.Current neuropharmacology · 2025Pooled it
- The impact of organisational factors on treatment outcomes for those seeking alcohol or other drug treatment: A systematic review.Drug and alcohol review · 2023Pooled it
- The role of nicotinic receptors in alcohol consumption.Pharmacological research · 2023Pooled it
- Effects of 10 add-on HF-rTMS treatment sessions on alcohol use and craving among detoxified inpatients with alcohol use disorder: a randomized sham-controlled clinical trial.Addiction (Abingdon, England) · 2023Trial
- Multi-omics and electrophysiological examination of GABAMolecular psychiatry · 2026Article
- Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.Clinical and molecular hepatology · 2026Review
- Perineuronal Net and Inhibitory Synapse Remodeling on Striatal Fast-Spiking Interneurons by Chronic Alcohol Exposure.Biological psychiatry · 2026Article
- Comparative effectiveness of gabapentin and pregabalin on reduction in alcohol use: A nationwide observational cohort study.medRxiv : the preprint server for health sciences · 2026Article
- Behavioral impact of condensed repeated ethanol dosing on withdrawal in adult zebrafish (Frontiers in systems neuroscience · 2026Article
- Trialing addiction neurocircuitry targets and directionality of brain stimulation effects: A deep TMS/fMRI trial in people with alcohol use disorder.Contemporary clinical trials communications · 2025Article
- Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study.Brain sciences · 2025Review
- Fatal Disulfiram-Ethanol Reaction in a Patient With Preexisting Cardiac Comorbidities: A Case Report.Cureus · 2025Article
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.Psychopharmacology · 2025Article
- An ultra low frequency spike timing dependent plasticity based approach for reducing alcohol drinking.Scientific reports · 2024Article
- A Survey of Medication Diffusion and Attitudes Among Indian Clinicians Toward Pharmacotherapies for Alcohol Use Disorder.Indian journal of psychological medicine · 2024Article
- Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: a multi-omics study.Translational psychiatry · 2024Article
- Alcohol metabolism in alcohol use disorder: a potential therapeutic target.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Review
- The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.Current medicinal chemistry · 2024Review
- Psychedelic therapy in the treatment of addiction: the past, present and future.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Alcohol use disorder is a heterogeneous illness with a complex biology that is controlled by many genes and gene-by-environment interactions. Several efficacious, evidence-based treatments currently exist for treating and managing alcohol use disorder, including a number of pharmacotherapies that target specific aspects of biology that initiate and maintain dangerous alcohol misuse. This article reviews the neurobiological and neurobehavioral foundation of alcohol use disorder, the mechanisms of action and evidence for the efficacy of currently approved medications for treatment, and the literature on other emerging pharmacotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.